NAVB Key Stats
- Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Joi... May 22
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Defin... May 16
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awareness May 15
- Nordion signs contract manufacturing agreement with Navidea May 15
- Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion Business Wire May 15
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 10
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and F... May 9
- Navidea Biopharmaceuticals, Inc Management Discusses Q1 2013 Results - Earnings ... May 8
- Navidea Biopharma (NAVB) Posts Narrower than Expected Q1 Loss Street Insider May 8
- Q1 2013 Navidea Biopharmaceuticals Inc Earnings Release - Before Market Open May 8
NAVB Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Navidea Biopharmaceuticals is down 11.27% over the last year vs S&P 500 Total Return up 27.77%, Abiomed up 0.27%, and Guided Therapeutics up 1.18%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for NAVB
Pro Report PDF for NAVB
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NAVB Pro Report PDF
Pro Strategies Featuring NAVB
Did Navidea Biopharmaceuticals make it into our Pro Portfolio Strategies?